Search

Author/Creator Mobasher, Mehrdad

1. 325 Immunotherapy with B cell activating antibody CPI-006 in patients (pts) with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells and memory T effector cells. (10th December 2020)

Authors:
Criner, Gerard; Mobasher, Mehrdad; Hill, Craig; Hu, Shenshen; Mahabhashyam, Suresh; Brody, Joshua; Marron, Thomas; Willingham, Stephen; Miller, Richard
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A199
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 325 Immunotherapy with B cell activating antibody CPI-006 in patients (pts) with mild to moderate COVID-19 stimulates anti-SARS-CoV-2 antibody response, memory B cells and memory T effector cells. (9th November 2020)

Authors:
Criner, Gerard; Mobasher, Mehrdad; Hill, Craig; Hu, Shenshen; Mahabhashyam, Suresh; Brody, Joshua; Marron, Thomas; Willingham, Stephen; Miller, Richard
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A351
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Abstracts from the 5th International Workshop on Positron Emission Tomography in Lymphoma held in Menton, France, 19–20 September 2014. Issue 5 (May 2015)

Authors:
Zwarthoed, Cholette; Ouvier, Matthieu John; Borra, Anna; Bergesio, Fabrizio; Chauvie, Stephane; Biggi, Alberto; Hutchings, Martin; El-Galaly, Tarek; Gallamini, Andrea; Simon, Zsófia; Miltényi, Zsófia; Magyari, Ferenc; Barna, Sándor; Kenyeres, Anna; Jóna, Ádám; Illés, Árpád; Dann, Eldad J.; Bar-Sh...
Journal:
Leukemia & lymphoma
Issue:
Volume 56:Issue 5(2015:May)
Page Start:
1233
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study. Issue 4 (21st March 2019)

Authors:
Sharman, Jeff P.; Forero-Torres, Andres; Costa, Luciano J.; Flinn, Ian W.; Inhorn, Lowell; Kelly, Kevin; Bessudo, Alberto; Fayad, Luis E.; Kaminski, Mark S.; Evens, Andrew M.; Flowers, Christopher R.; Sahin, Deniz; Mundt, Kirsten E.; Sandmann, Thomas; Fingerle-Rowson, Günter; Vignal, Charlotte; M...
Journal:
Leukemia & lymphoma
Issue:
Volume 60:Issue 4(2019)
Page Start:
894
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Issue 7 (July 2019)

Authors:
Soumerai, Jacob D; Ni, Ai; Darif, Mohamed; Londhe, Anil; Xing, Guan; Mun, Yong; Kay, Neil E; Shanafelt, Tait D; Rabe, Kari G; Byrd, John C; Chanan-Khan, Asher A; Furman, Richard R; Hillmen, Peter; Jones, Jeffrey; Seymour, John F; Sharman, Jeffrey P; Ferrante, Lucille; Mobasher, Mehrdad; Stark, Th...
Journal:
Lancet
Issue:
Volume 6:Issue 7(2019)
Page Start:
e366
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial. Issue 3 (March 2022)

Authors:
Kersting, Sabina; Dubois, Julie; Nasserinejad, Kazem; Dobber, Johan A; Mellink, Clemens; van der Kevie-Kersemaekers, Anne-Marie F; Evers, Ludo M; de Boer, Fransien; Koene, Harry R; Schreurs, John; van der Klift, Marjolein; Velders, Gerjo A; van der Spek, Ellen; van der Straaten, Hanneke M; Hoogen...
Journal:
Lancet
Issue:
Volume 9:Issue 3(2022)
Page Start:
e190
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Issue 6 (June 2016)

Authors:
Stilgenbauer, Stephan; Eichhorst, Barbara; Schetelig, Johannes; Coutre, Steven; Seymour, John F; Munir, Talha; Puvvada, Soham D; Wendtner, Clemens-Martin; Roberts, Andrew W; Jurczak, Wojciech; Mulligan, Stephen P; Böttcher, Sebastian; Mobasher, Mehrdad; Zhu, Ming; Desai, Monali; Chyla, Brenda; Ve...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 6(2016:Jun.)
Page Start:
768
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗